{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-157.2","upperLimit":"39.3","value":"-7.60"}]}],"title":"Change from baseline @ Month 2.75"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-99.2","upperLimit":"39.3","value":"-5.98"}]}],"title":"Change from baseline @ Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-149.8","upperLimit":"39.3","value":"-7.27"}]}],"title":"Change from baseline @ Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-163.8","upperLimit":"39.3","value":"-8.83"}]}],"title":"Change from baseline @ Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-159.2","upperLimit":"3.0","value":"-8.90"}]}],"title":"Change from baseline @ Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-23.9","upperLimit":"39.3","value":"-15.68"}]}],"title":"Change from baseline @ Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-25.5","upperLimit":"-1.4","value":"-16.67"}]}],"title":"Change from baseline @ Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"This shows the change in mean GH levels from baseline in median GH levels by visit.","dispersionType":"Full Range","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"MEDIAN","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\\> 40mg -\\>20mg -\\> 40mg -\\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.","reportingStatus":"POSTED","timeFrame":"Baseline, Months 2.75, 3, 6, 9, 12, 18, 24","title":"Change in Mean GH Levels From Baseline","type":"SECONDARY","unitOfMeasure":"ug/L"}